Skip to main content
. 2021 Jul 23;27(4):589–602. doi: 10.3350/cmh.2021.0038

Figure 4.

Figure 4.

Subgroup analysis according to the presence of MiVI. Time to recurrence (A) and overall survival (B) according to EVR use in patients without MiVI. Time to recurrence (C) and overall survival (D) according to EVR use in patients with MiVI. MiVI, microscopic vascular invasion; EVR, everolimus.